TNFRSF10A and leukemia: Accordingly, expression of DR4 and/or DR5 is a critical factor in the susceptibility of leukemia cells to the anti-leukemic activity of TRAIL and consequently to immunotherapies using the CAR T-cells and blinatumomab as well as the GVL effect after allo-SCT (Figure 1A).